

Supporting Information

Improved Binding Affinity and Interesting Selectivities of Aminopyrimidine-Bearing Carbohydrate Receptors in Comparison with their Aminopyridine Analogues

Jan Lippe, Wilhelm Seichter and Monika Mazik*

Institut für Organische Chemie, Technische Universität Bergakademie Freiberg,

Leipziger Straße 29, 09596 Freiberg, Germany

monika.mazik@chemie.tu-freiberg.de

1. Representative WinEQNMR plots (Figures S1-S6)
2. Representative HypNMR plots (Figures S7-S9)
3. Representative mole ratio plots (Figures S10-S12)
4. ^1H NMR titrations of compound **8**, **10**, **12** and **14** with the tested carbohydrates (Figures S13 and S14)
5. Molecular modelling calculations (Figure S15)
6. Crystallographic data (Tables S1 and S2, Figure S16)
7. ^1H and ^{13}C NMR spectra of compounds **8-10** and **12-14** (Figures S17-32)

1 Plots of the chemical shifts of the receptor resonances as a function of added carbohydrate (WinEQNMR program).




Figure S1. Plot of the observed chemical shifts of the NH resonances of **12** as a function of added β -galactoside **23** in CDCl_3 (1:1 and 1:2 receptor-sugar binding model).




Figure S2. Plot of the observed chemical shifts of the pyrimidine CH resonances of **8** as a function of added β -glucoside **22** in CDCl_3 (1:1 and 2:1 receptor-sugar binding model).




Figure S3. Plot of the observed chemical shifts of the Pyrimidin-CH resonances of **8** as a function of added β -galactoside **23** in CDCl_3 (1:1 and 2:1 receptor-sugar binding model).




Figure S4. Plot of the observed chemical shifts of the pyrimidine CH resonances of **10** as a function of added β -glucoside **22** in 5/95 $\text{DMSO-d}_6/\text{CDCl}_3$ v/v (1:1 and 1:2 receptor-sugar binding model).




Figure S5. Plot of the observed chemical shifts of the pyrimidine CH resonances of **10** as a function of added β -galactoside **23** in CDCl_3 (1:1 and 1:2 receptor-sugar binding model).




Figure S6. Plot of the observed chemical shifts of the NH resonances of **14** as a function of added β -galactoside **23** in CDCl_3 (1:1 and 1:2 receptor-sugar binding model).

2 Representative HypNMR plots.




Figure S7. Plot of the calculated (line) and experimental (points) $\Delta\delta$ of pyrimidine CH (A), CHNH (B) and NH (C) signals of **8** as a function of added β -glucoside **22** in 5/95 $\text{DMSO-d}_6/\text{CDCl}_3$ (v/v). All signals are fitted simultaneously. For a better representation a secondary axis is used for C.




Figure S8. Plot of the calculated (line) and experimental (points) $\Delta\delta$ of pyrimidine *CH* (A) and *CHNH* (B) signals of **10** as a function of added β -glucoside **22** in 5/95 DMSO- d_6 /CDCl $_3$ (v/v). All signals are fitted simultaneously.




Figure S9. Plot of the calculated and experimental $\Delta\delta$ of pyrimidine *CH* (A) and *CHNH* (B) signals of **8** as a function of added β -glucoside **22** in CDCl $_3$; the signals are fitted simultaneously. The binding constants were too large to be accurately determined by the NMR method.

3 Representative mole ratio plots.




Figure S10. Mole ratio plot: Titration of compound **12** with β -glucopyranoside **22** in CDCl_3 (analysis of the complexation-induced shift of the NH signal of **12**).




Figure S11. Mole ratio plot: Titration of compound **10** with β -galactopyranoside **23** in CDCl_3 (analysis of the complexation-induced shift of the pyrimidine CH signal of **10**).




Figure S12. Mole ratio plot: Titration of compound **8** with α -glucopyranoside **24** in CDCl_3 (analysis of the complexation-induced shift of the NH signal of **8**).

4 ^1H NMR titrations of compounds **8**, **10**, **12** and **14** with the tested carbohydrates (examples).




Figure S13. Partial ^1H NMR spectra of receptors (a) **12**, (b) **10**, and (c) **8** before (bottom) and after the addition of β -galactoside **23** in CDCl_3 ; (a) $[\mathbf{12}] = 1.05$ mM, equiv. of **23**: 0.00-4.76; (b) $[\mathbf{10}] = 1.00$ mM, equiv. of **23**: 0.00-6.00; (c) $[\mathbf{8}] = 1.02$ mM, equiv. of **23**: 0.00-5.46. Shown are (from left to right) the pyrimidine CH and the CH_2 signals of the corresponding receptor.




Figure S14. Partial ^1H NMR spectra of (a) the triethylbenzene-based receptor **12** and (b) the trimethoxybenzene-based **14** after addition of 0.00-4.70 or 0.00-5.18 equiv β -glucopyranoside **22**, respectively, in CDCl_3 ; $[\mathbf{12}] = 1.06$ mM, $[\mathbf{14}] = 1.02$ mM]. Shown are the NH-CH_2 signals of the corresponding receptor.

5 Molecular modelling calculations (examples).




Figure S15. Energy-minimized structures of compounds (a) **8** and (b) **10** as well as of the 1:1 complexes (c) **8•24**, (d) **12•22**, (e) **13•23** and (f) **14•22**. MacroModel V.9.8, OPLS_2001 force field, MCMM, 50000 steps; $\epsilon = 1$ [F/m]. Color code: receptor N, blue; receptor C, grey; the sugar molecule is highlighted in orange.

6 Crystallographic data (Tables S1 and S2, Figure S11).

Table S1. Relevant conformational parameters of the receptor molecule in the crystal structure of **12**.

<i>dihedral angle</i> (°) ^a			
mpla(A)···mpla(B)	82.1(1)	mpla(A')···mpla(B')	75.0(1)
mpla(A)···mpla(C)	83.2(1)	mpla(A')···mpla(C')	82.2(1)
mpla(A)···mpla(C)	84.7(1)	mpla(A')···mpla(C')	77.0(1)
mpla(B)···mpla(C)	36.4(1)	mpla(B')···mpla(C')	39.1(1)
mpla(B)···mpla(D)	64.0(1)	mpla(B')···mpla(D')	51.9(1)
mpla(C)···mpla(D)	36.4(1)	mpla(C')···mpla(D')	87.5(1)
<i>torsion angle</i> (°)			
C(1)-C(13)-N(1)-C(14)	168.8(1)	C(1A)-C(13A)-N(1A)-C(14A)	170.6(1)
C(3)-C(20)-N(4)-C(21)	-127.9(1)	C(3A)-C(20A)-N(4A)-C(21A)	151.3(1)
C(5)-C(27)-N(7)-C(28)	-154.1(1)	C(5A)-C(27A)-N(7A)-C(28A)	-178.9(1)

Table S2. Distances (Å) and Angles (deg) of Non-covalent Interactions of the compound **12**.

D-H...A Cg...Cg	symmetry operator	D...A	H...A	D-H...A	
N(1)-H(1)···N(6A)	x, y, z	3.093(2)	2.21(1)	176(2)	Fig. S1/ a
N(4)-H(4)···N(5A)	x, y, z	3.230(2)	2.40(1)	157(2)	Fig. S1/ b
N(4A)-H(4A)···N(5)	x, y, z	2.992(2)	2.14(1)	162(1)	Fig. S1/ c
N(1A)-H(1A)···C(23) ^a	x, y, z	3.649(3)	2.77(1)	170(2)	
N(7)-H(7)···C(23A) ^a	x, y, z	3.350(3)	2.49(1)	166(2)	Fig. S1/ d
N(7A)-H(7A)···N(2A)	$2-x, 2-y, -z$	3.263(2)	2.47(1)	150(2)	
O(1W)-H(1W)···N(8) ^c	x, y, z	3.187(3)	2.34	179	Fig. S1/ e
O(1W)-H(2W)···N(9A) ^c	$x, y, 1+z$	3.078(2)	2.23	133	
C(7)-H(7AA)···N(6)	x, y, z	3.561(2)	2.62	160	Fig. S1/ f
C(7A)-H(7AD)···N(1A)	x, y, z	3.352(2)	2.62	131	Fig. S1/ g
C(19)-H(19B)···N(6)	$1+x, y, z$	3.504(3)	2.58	158	
C(19A)-H(19F)···O(1W)	$1-x, 2-y, 1-z$	3.363(3)	2.62	133	
C(20A)-H(20C)···N(2)	x, y, z	3.370(2)	2.69	127	
C(16)-H(16)···Cg(C) ^b	$1+x, y, z$	3.633(3)	2.78	150	
C(19)-H(19C)···Cg(A) ^b	$2-x, 2-y, 1-z$	3.452(3)	2.60	145	
C(26)-H(26B)···N(3A)	x, y, z	3.551(2)	2.58	171	Fig. S1/ h
C(11A)-H(11C)···N(7A)	x, y, z	3.217(2)	2.51	128	Fig. S1/ i
C(30A)-H(30A)···Cg(C') ^b	$2-x, 1-y, -z$	3.758(3)	2.82	169	
Cg(A)···Cg(C') ^b	x, y, z	3.791(2)			Fig. S1/ j

^a In order to obtain a reasonable hydrogen bond geometry an individual atom instead of the center of the aromatic ring was chosen as an acceptor.

^b Cg means the centroid of the aromatic ring. Ring A: C(1)...C(6); ring C: N(5),N(6),C(21)...C(24); ring C': N(5A),N(6A),C(21A)...C(24A).

^c The water hydrogen atoms were included in the model in positions which allow reasonable hydrogen bond geometries.




Figure S16. Perspective view of the molecular structure **1**•H₂O (2:1). The aromatic rings of one molecule are marked as A-D, whereas those of the second molecule as A'-D'; the distances and angles of the noncovalent interactions **a-j** are given in Table S2. The thermal ellipsoids are drawn at the 50% probability level. Nitrogen atoms are displayed as blue, the oxygen atom as red ellipsoids. Dashed lines represent hydrogen bonds, dashed double lines $\pi \cdots \pi$ are arene stacking.

7. ^1H and ^{13}C NMR spectra of compounds **8-10** and **12-14** (Figures S12-27).

7.1 ^1H and ^{13}C NMR spectra of compound **8**.




Figure S17. ^1H NMR spectrum of **8** in CDCl_3 (0.03 M).




Figure S18. ^{13}C NMR spectrum of **8** in CDCl_3 .




Figure S19. DEPT spectrum of **8** in CDCl_3 .

7.2 ^1H and ^{13}C NMR spectra of compound **9**.




Figure S20. ^1H NMR spectrum of **9** in CDCl_3 (0.04 M).




Figure S21. ^{13}C NMR spectrum of **9** in CDCl_3 .

7.3 ^1H and ^{13}C NMR spectra of compound **10**.




Figure S22. ^1H NMR spectrum of **10** in CDCl_3 (0.03 M).




Figure S23. ^{13}C NMR spectrum of **10** in CDCl_3 .




Figure S24. DEPT spectrum of **10** in CDCl_3 .

7.4 ^1H and ^{13}C NMR spectra of compound **12**.




Figure S25. ^1H NMR spectrum of **12** in CDCl_3 (0.06 M).




Figure S26. ^{13}C NMR spectrum of **12** in CDCl_3 .




Figure S27. DEPT spectrum of **12** in CDCl_3 .

7.5 ^1H and ^{13}C NMR spectra of compound **13**.




Figure S28. ^1H NMR spectrum of **13** in CDCl_3 (0.03 M).




Figure S29. ^{13}C NMR spectrum of **13** in CDCl_3 .




Figure S30. DEPT spectrum of **13** in CDCl_3 .

7.6 ^1H and ^{13}C NMR spectra of compound **14**.




Figure S31. ^1H NMR spectrum of **14** in CDCl_3 (0.02 M).




Figure S32. ^{13}C NMR spectrum of **14** in CDCl_3 .